CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Oct. 31, 2015	Oct. 31, 2014
Cash flows from operating activities
Net income	$ 14,254	$ 11,239
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	2,822	2,312
Amortization	3,094	2,956
Stock-based compensation expense	1,720	1,581
Amortization of debt issuance costs	100	100
Loss on disposal of fixed assets	100	13
Fair value adjustments to acquisition related liabilities	(592)	147
Deferred income taxes	1,322	1,488
Excess tax benefits from stock-based compensation	(1,489)	(2,473)
Changes in assets and liabilities, net of assets acquired and liabilities assumed:
Accounts receivable	(236)	(2,950)
Inventories	(2,295)	(1,389)
Prepaid expenses and other current assets	(5,534)	(783)
Accounts payable and other current liabilities	(3,005)	(4,087)
Income taxes	4,854	4,549
Net cash provided by operating activities	15,115	12,703
Cash flows from investing activities
Capital expenditures	(3,167)	(3,055)
Proceeds from disposal of fixed assets		15
Acquisition of Medical Innovations, net of cash acquired	(79,810)
Restricted cash for IMS Acquisition		(24,257)
Net asset value adjustment for PuriCore Acquisition		337
Other, net	(12)	(56)
Net cash used in investing activities	(82,989)	(27,016)
Cash flows from financing activities
Borrowings under revolving credit facility	83,000	25,000
Repayments under revolving credit facility	(14,000)	(12,000)
Proceeds from exercises of stock options		323
Excess tax benefits from stock-based compensation	1,489	2,473
Purchases of treasury stock	(3,138)	(3,274)
Net cash provided by financing activities	67,351	12,522
Effect of exchange rate changes on cash and cash equivalents	(66)	(276)
Decrease in cash and cash equivalents	(589)	(2,067)
Cash and cash equivalents at beginning of period	31,720	31,781
Cash and cash equivalents at end of period	$ 31,131	$ 29,714